Interferon α-2b Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Interferon α-2b is U.S. Food and Drug Administration (FDA) approved for the treatment of stage IIB and stage III disease. Treatment for 1 year resulted in a prolonged survival (2.8 years compared with 3.8 years and prolongation of disease-free survival from 1.0 to 1.7 years). The Sunbelt Melanoma Trial is under way and will attempt to answer the benefit of interferon therapy and the significance of lymph nodes that are positive only by PCR analysis.
Interferon α-2b Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
